Zacks Research Issues Positive Forecast for TriMas Earnings

Key Points

• Zacks Research raised its Q2 2026 earnings estimate for TriMas Corporation from $0.51 to $0.60 per share, while the consensus estimate for the full year is $1.69 per share.
• TriMas reported a 14.2% year-over-year increase in revenue for the last quarter, totaling $274.76 million, and exceeded analysts' estimates of $251.18 million.
• The company recently declared a quarterly dividend of $0.04 per share, representing an annualized dividend of $0.16 and a yield of 0.4%.

TriMas Corporation (NASDAQ:TRS - Free Report) - Zacks Research lifted their Q2 2026 earnings estimates for TriMas in a research note issued to investors on Tuesday, August 12th. Zacks Research analyst M. Das now anticipates that the industrial products company will post earnings of $0.60 per share for the quarter, up from their prior estimate of $0.51. The consensus estimate for TriMas' current full-year earnings is $1.69 per share. Zacks Research also issued estimates for TriMas' Q3 2026 earnings at $0.55 EPS, FY2026 earnings at $2.00 EPS, Q1 2027 earnings at $0.49 EPS and Q2 2027 earnings at $0.56 EPS.

TriMas (NASDAQ:TRS - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The industrial products company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.11. The firm had revenue of $274.76 million during the quarter, compared to the consensus estimate of $251.18 million. TriMas had a return on equity of 11.49% and a net margin of 3.83%.The company's quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 EPS. TriMas has set its FY 2025 guidance at 1.950-2.100 EPS.

Several other equities research analysts have also recently issued reports on TRS. Wall Street Zen raised shares of TriMas from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. BWS Financial reissued a "buy" rating and set a $45.00 price objective (up previously from $40.00) on shares of TriMas in a research note on Wednesday, July 30th. Finally, KeyCorp set a $45.00 target price on shares of TriMas and gave the stock an "overweight" rating in a research note on Tuesday, August 12th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $45.00.

TriMas Price Performance

Shares of NASDAQ:TRS traded up $0.0950 on Thursday, hitting $36.9150. The company had a trading volume of 236,612 shares, compared to its average volume of 419,750. The company has a market cap of $1.50 billion, a PE ratio of 40.54 and a beta of 0.66. The business has a 50 day moving average of $31.09 and a 200 day moving average of $26.16. TriMas has a 52-week low of $19.33 and a 52-week high of $37.49. The company has a current ratio of 2.59, a quick ratio of 1.44 and a debt-to-equity ratio of 0.59.

Institutional Investors Weigh In On TriMas

Several hedge funds have recently modified their holdings of TRS. State of Wyoming acquired a new position in TriMas during the 2nd quarter worth approximately $65,000. Tower Research Capital LLC TRC raised its stake in shares of TriMas by 280.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,193 shares of the industrial products company's stock valued at $120,000 after purchasing an additional 3,091 shares during the period. Captrust Financial Advisors acquired a new position in shares of TriMas during the second quarter worth $355,000. Tidal Investments LLC purchased a new position in shares of TriMas in the second quarter valued at $220,000. Finally, Man Group plc acquired a new stake in TriMas during the 2nd quarter valued at $294,000. 99.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at TriMas

In other news, Director Adrianne Shapira purchased 4,000 shares of the company's stock in a transaction on Thursday, June 5th. The stock was bought at an average cost of $25.82 per share, for a total transaction of $103,280.00. Following the completion of the purchase, the director directly owned 8,476 shares of the company's stock, valued at $218,850.32. The trade was a 89.37% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Shawn Sedaghat bought 72,937 shares of the firm's stock in a transaction dated Thursday, May 22nd. The shares were purchased at an average price of $26.16 per share, with a total value of $1,908,031.92. Following the acquisition, the director directly owned 1,883,758 shares in the company, valued at approximately $49,279,109.28. This trade represents a 4.03% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 488,375 shares of company stock valued at $12,475,894. 14.20% of the stock is owned by company insiders.

TriMas Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 12th. Investors of record on Tuesday, August 5th were issued a $0.04 dividend. The ex-dividend date was Tuesday, August 5th. This represents a $0.16 dividend on an annualized basis and a yield of 0.4%. TriMas's dividend payout ratio (DPR) is presently 17.58%.

TriMas Company Profile

TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.